Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$26.97 USD

26.97
2,911,983

-0.20 (-0.74%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $26.97 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Biotech Stock Roundup: NKTR Plunges on Study Failure, MRNA Offers Updates & More

Pipeline and regulatory updates from Nektar (NKTR) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.

Exelixis (EXEL) Announces Final Results From HCC Study

Exelixis (EXEL) does not intend to submit a supplemental new drug application to the FDA for Cabometyx in patients with previously untreated advanced hepatocellular carcinoma.

Exelixis (EXEL) Q4 Earnings & Revenues Beat, Cabometyx Strong

Exelixis (EXEL) beats on both earnings and revenues in the fourth quarter. Both figures increase on a year-over-year basis.

Exelixis (EXEL) Tops Q4 Earnings and Revenue Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of 314.29% and 26.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More

Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.

Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Exelixis (EXEL) Announces Preliminary Q4 Results, Issues View (Revised)

Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.

Exelixis (EXEL) Announces Preliminary Q4 Results, Issues View

Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.

Exelixis (EXEL) Amends Agreement With Iconic Therapeutics

Exelixis (EXEL) gains full rights to anti-tissue factor antibody used in XB002 plus oncology-specific rights to additional antibodies discovered by Iconic.

Exelixis (EXEL) Initiates Study on XL092 in Advanced Solid Tumors

Exelixis (EXEL) begins the dose-escalation stage of its study evaluating XL092 in combination with immuno-oncology therapies in patients with advanced solid tumors.

Exelixis (EXEL) Down 14.8% Since Last Earnings Report: Can It Rebound?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Merck's (MRK) Keytruda Gets Approval for Certain RCC Patients

Merck's (MRK) anti-PD-1 therapy Keytruda gets FDA nod as an adjuvant treatment for patients with renal cell carcinoma at intermediate-high or high risk of recurrence, following nephrectomy, or following nephrectomy and resection of metastatic lesions.

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)

Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market.

EXEL vs. ILMN: Which Stock Is the Better Value Option?

EXEL vs. ILMN: Which Stock Is the Better Value Option?

Exelixis (EXEL) Misses on Q3 Earnings & Revenues, Tweaks View

Exelixis (EXEL) misses on earnings and revenues in the third quarter. Both figures increase on a year-over-year basis.

Exelixis (EXEL) Q3 Earnings and Revenues Lag Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of -36.84% and -10.35%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) to Report Q3 Earnings: What's in the Cards?

On Novavax's (NVAX) upcoming third-quarter earnings call, investor focus is likely to be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.

Cassava Sciences (SAVA) to Post Q3 Earnings: What's in Store?

Investors will watch for updates on its lead candidate, sumifilam, for Alzheimer's disease in Cassava's (SAVA) Q3 earnings call.

Is a Surprise Coming for Exelixis (EXEL) This Earnings Season?

Exelixis (EXEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Will Eylea, Dupixent, REGEN COV Aid Regeneron (REGN) Q3 Earnings?

Regeneron's third-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.

CVS Health (CVS) to Report Q3 Earnings: What's in the Cards?

CVS Health's (CVS) consumer-centric digital approach to administering vaccines across the nation is expected to have strongly contributed to its Q3 performance.

Is a Beat in Store for Generac (GNRC) This Earnings Season?

Generac's (GNRC) third-quarter 2021 earnings are likely to have been driven by a solid demand environment and effective acquisition strategies supported by a resilient business model.

Is a Beat in Store for T-Mobile (TMUS) This Earnings Season?

T-Mobile's (TMUS) performance in the third quarter of 2021 is likely to have benefited from customer growth and 5G network expansion.